Unknown

Dataset Information

Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology.


ABSTRACT:

Background

There is increasing use of Phase I statistical designs to find a dose that causes rapidly emerging and particularly concerning severe or life-threatening toxicities (dose-limiting toxicities, DLTs) in a specified percent of patients most commonly 25%. While a convenient statistical framework, the foundation for selecting any specified target DLT rate, and its relevance to the recommended Phase II dose is generally lacking.

Method

We surveyed 78 medical oncologists, most (69%) with experience as a principal investigator on a Phase I study, to ascertain their opinions related to this approach to Phase I studies and the targets often chosen.

Results

Eighty-seven percent of respondents preferred severe toxicities in only 5%-10% of patients, consistent with 58%

SUBMITTER: Frankel PH 

PROVIDER: S-EPMC7647940 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature